Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Amlot

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Allergy|July 1, 1986
Histamine release from peripheral blood leucocytes in egg-allergic patientsP M Clinton, D M Kemeny, P Amlot, et al.
Leukemia & Lymphoma|May 1, 1994
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxinsA Engert, C Gottstein, U Winkler, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 15, 1992
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]A Engert, C Gottstein, U Winkler, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|December 19, 2007
Donor-derived human herpes virus 8-related Kaposi's sarcoma in renal allograft ureterT J Dudderidge, M Khalifa, R Jeffery, et al.
Lancet (London, England)|July 4, 1998
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study GroupB Nashan, R Moore, P Amlot, et al.
Cancer Research|May 15, 1990
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in miceA Engert, G Martin, M Pfreundschuh, et al.
Cancer Research|July 1, 1993
Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killingM A Bonardi, R R French, P Amlot, et al.
Nephron|January 1, 1989
Epstein-Barr-virus-associated lymphoproliferation arising in a renal allograftE R Maher, M E Chappell, P Amlot, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 5, 1999
Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcomeZ Ben-Ari, P Amlot, S R Lachmanan, et al.
Transplantation Proceedings|February 1, 1989
Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibodyT H Waid, B A Lucas, J S Thompson, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Allergy|July 1, 1986
Histamine release from peripheral blood leucocytes in egg-allergic patientsP M Clinton, D M Kemeny, P Amlot, et al.
Leukemia & Lymphoma|May 1, 1994
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxinsA Engert, C Gottstein, U Winkler, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 15, 1992
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]A Engert, C Gottstein, U Winkler, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|December 19, 2007
Donor-derived human herpes virus 8-related Kaposi's sarcoma in renal allograft ureterT J Dudderidge, M Khalifa, R Jeffery, et al.
Lancet (London, England)|July 4, 1998
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study GroupB Nashan, R Moore, P Amlot, et al.
Cancer Research|May 15, 1990
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in miceA Engert, G Martin, M Pfreundschuh, et al.
Cancer Research|July 1, 1993
Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killingM A Bonardi, R R French, P Amlot, et al.
Nephron|January 1, 1989
Epstein-Barr-virus-associated lymphoproliferation arising in a renal allograftE R Maher, M E Chappell, P Amlot, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 5, 1999
Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcomeZ Ben-Ari, P Amlot, S R Lachmanan, et al.
Transplantation Proceedings|February 1, 1989
Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibodyT H Waid, B A Lucas, J S Thompson, et al.
Pageof 5